Therapeutic Drug Monitoring in HIV Treatment: A Literature Review

REFERENCES

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87.
   PubMed Web of Science ®Google Scholar
• Casado JL, Perez-Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a co-hort of HIV-infected patients. AIDS. 1998;12:F131–135.
   PubMed Web of Science ®Google Scholar
• Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts out-come of therapy. AIDS. 1999;13:F71–77.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 200115: 71–75.
   Google Scholar
• Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002;16:2311–2315.
   PubMed Web of Science ®Google Scholar
• Mellolas J, Blanco JL, Sarasa M, et al. Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients. J Acquir Immune Defic Syndr. 2000,25:229–235.
   PubMed Web of Science ®Google Scholar
• Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials. 2000;1:13–19.
   PubMedGoogle Scholar
• Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-posi-tive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:453–460.
   PubMed Web of Science ®Google Scholar
• Barry MG, Merry C, Lloyd J, et al. Variability in trough plasma saquinavir concentrations in HIV patients-a case for therapeutic drug monitoring. Br J Clin Pharmacol. 1998;45:501–502.
   PubMed Web of Science ®Google Scholar
• Back D, Gatti G, Fletcher C, et al. Therapeutic drug moni-toring in HIV infection: current status and future directions. AIDS. 2002,16 (suppl 1):S5–37.
   PubMed Web of Science ®Google Scholar
• Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996;10:485–492.
   PubMed Web of Science ®Google Scholar
• Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treat-ment failure in HIV-1-infected patients on indinavir-con-taining triple therapy. Antivir Ther. 1998,3:215–220.
   PubMed Web of Science ®Google Scholar
• Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171:537–545.
   PubMed Web of Science ®Google Scholar
• Veldkamp Al, Weverling GJ, Lange JM, et al. High expo-sure to nevirapine in plasma is associated with an im-proved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089–1095.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930–937.
   PubMed Web of Science ®Google Scholar
• Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS. 1998;12:F111–115.
   PubMed Web of Science ®Google Scholar
• Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interac-tion between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999;179:1116–1123.
   PubMed Web of Science ®Google Scholar
• Aries SP, Schaaf BM, Wilmsen U, et al. Routine therapeutic drug monitoring in patients on protease inhibitors: impact on therapeutic decisions? 5th International Congress on Drug Therapy in HIV Infection [abstract P264 A]. AIDS. 2000,14\(suppl 4):591.
   Google Scholar
• Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473–478.
   PubMed Web of Science ®Google Scholar
• Lloyd J, Maher B, Khoo S, Gibbons S, Back D. The feasibil-ity of therapeutic drug monitoring for protease inhibitors [abstract]. In: Program and abstracts from the 6th Annual Conference of the British HIV Association; March 2000; Edinburgh, Scotland.
   Google Scholar
• Martinavarro-Dominguez A, Capella-Peiro ME, Gil-Agusti M, Marcos-Tomas JV, Esteve-Romero J. Therapeutic drug monitoring of anticonvulsant drugs by micellar HPLC with direct injection of serum samples. Clin Chem. 2002;48:1696–1702.
   PubMed Web of Science ®Google Scholar
• Abendroth D. Experience with therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36:4265–4295.
   Web of Science ®Google Scholar
• Begg EJ, Barclay ML. Aminoglycosides-50 years on. Br J Clin PharmacoL 1995;39:597–603.
   PubMed Web of Science ®Google Scholar
• Recommendations du Groupe d'Experts. Rapport 2000 Sous la Direction du Pr JF Delfraissy. Prise en Charge Therapeutique des Personnes Infectees par le VIH. Paris: Medecine-Sciences, Flamarion; 2000.
   Google Scholar
• Doerr HW, Brockmeyer NH, Salzberger B, Marcus U, Brodt HR. Antiretrovirale Therapie der HIV-Infektion. Deutsches Arzteblatt. 2001;4: 175–181.
   Google Scholar
• Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. Analysis of varia-tion in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS. 2001,15:991–998.
   PubMed Web of Science ®Google Scholar
• Burger DM, Hugen PW, Aarnoutse RE, et al. A retrospec-tive, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr. 200126: 218–224.
   Google Scholar
• Burger D, Hugen P, Reiss P, et al. Therapeutic drug moni-toring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157–1165.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Anderson PL, Kakuda TN, et al. Concentra-tion-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551–560.
   PubMed Web of Science ®Google Scholar
• Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in asso-ciation with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5:352–359.
   PubMed Web of Science ®Google Scholar
• Duval X, Mentre F, Lamotte C, et al. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. Ther Drug Monit. 2005;27:63–70.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV in-fection. J Infect Dis. 1998;177:1533–1540.
   PubMed Web of Science ®Google Scholar
• Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS. 2002;16:1331–1340.
   PubMed Web of Science ®Google Scholar
• Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellu-lar and plasma pharmacological parameters predicting re-sponse to lopinavir/ritonavir (KALEPHAR study). AIDS. 2004;18:1305–1310.
   PubMed Web of Science ®Google Scholar
• Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit. 2004;26:267–270.
   PubMed Web of Science ®Google Scholar
• Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73–80.
   PubMed Web of Science ®Google Scholar
• Rayner CR, Galbraith KJ, Marriott JL, Duncan GJ. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother. 2002;36:1230–1237.
   PubMed Web of Science ®Google Scholar
• John L, Marra F, Ensom MH. Role of therapeutic drug monitoring for protease inhibitors. Ann Pharmacother. 200135: 745–754.
   Google Scholar
• Molto J, Clotet B. Therapeutic drug monitoring of antiretroviral agents scenario. J HIV Ther. 2004;9:75–78.
   PubMedGoogle Scholar